

【英語論文】 \*, Corresponding Author

**2022**

1. Cho KY, **Miyoshi H\***, Nakamura A, Greenberg AS, Atsumi T. Lipid droplet protein PLIN1 regulates inflammatory polarity in human macrophages and is involved in atherosclerotic plaque development by promoting stable lipid storage. *J Atheroscler Thromb.* 2022 in press
2. Oba-Yamamoto C, Takeuchi J, Nakamura A, Nomoto H, Kameda H, Cho KY, Atsumi T, **Miyoshi H\***. Impact on postprandial blood glucose in low starch high fiber pasta. *Nutr Metab Cardiovasc Dis.* 32(2):487-493, 2022
3. Seino Y, **Miyoshi H**, Traberg HB, Divyalasya TVS, Nishijima K, Terauchi Y. A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg. *J Diabetes Invest.* 2022 in press
4. Kawata S, Nakamura A, **Miyoshi H**, Yang K, Shigesawa I, Yamauchi Y, Tsuchida K, Omori K, Takahashi K, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T. Glucokinase activation leads to an unsustained hypoglycaemic effect with hepatic triglyceride accumulation in db/db mice. *Diabetes Obes Metab.* 24(3):391-401,2022
5. Chiba K, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Jin S, Matoba K, **Miyoshi H**, Atsumi T. False hypercortisolemia due to abnormal albumin-cortisol binding in a patient with familial dysalbuminemic hyperthyroxinemia. *Thyroid.* 32(2):219-220,2022
6. Takahashi Y, Kameda H, Miya A, Nomoto H, Cho KY, Nakamura A, Nishimura H, Shimizu A, Okamoto M, Motegi H, Iwata N, **Miyoshi H**, Atsumi T. Lymphocytic panhypophysitis and anti-rabphilin-3A antibody with pulmonary sarcoidosis. *Pituitary.* 25(2):321-327,2022
7. Nomoto H, Furusawa S, Nakamura A, Takeuchi J, Nagai S, Yokoyama H, Sakuma I, Taneda S, Kurihara Y, Aoki S, Miya A, Kameda H, Cho KY, Atsumi T, **Miyoshi H\***. Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multi-center, prospective, randomized, open-label, blinded endpoint parallel-group comparison study (the SWITCH-SEMA 2 study). *BMJ Open.* 2022 *In press*
8. Goudarzi H, Kimura H, Kimura H, Makita H, Matsumoto M, Takei N, Shimizu K, Suzuki M, Watanabe T, Kikuchi E, Ohira H, Tsujino I, Sakakibara-Konishi J, Shinagawa N, Shijubo N, Sato H, Shigehara K, Kaga K, Hida Y, Murakami S, Ebihara Y, Nakamura A, **Miyoshi H**, Hirano S, Hizawa N, Atsumi T, Huang S, Ito Y, Nishimura M, Konno S. Effects of obesity on CC16 and their potential role in overweight/obese asthma. *Respiratory Research.* 2022 *in press*
9. Miya A, Nakamura A, Yokota I, Cho KY, Kameda H, Nomoto H, Takase T, Omori K, Ono M, Nagai S, Taneda S, **Miyoshi H**, Atsumi T. The agreement between measured HbA1c and optimized target HbA1c based on the Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8): A cross-sectional study of elderly patients with diabetes. *Geriatr Gerontol Int.* 2022 *in press*

10. Tsuzuki A, Fujioka Y, Yoshida A, Kashiwagi S, Amano M, Hira T, Nakamura A, **Miyoshi H**, Atsumi T, Ohba Y. Direct visualization of GLP-1 secretion by fluorescent fusion proteins. *J Diabetes Invest.* 2022 *in press*

### 2021

11. **Miyoshi H\***, Baxter M, Kimura T, Hattori M, Morimoto Y, Marinkovich D, Tamiwa M, Hirose T. A real-world, observational study of the initiation, use, and effectiveness of basal-bolus or premixed insulin in Japanese people with type 2 diabetes. *Diabetes Ther.* 12:1341-1357, 2021
12. Kameda R, Cho KY, Nomoto H, MD, Nakamura A, Omori K, MD, Nagai S, MD, PhD3, Takeuchi J, Kurihara Y, Aoki S, Atsumi T, MD, **Miyoshi H\***; LUNA Study Investigators. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: a multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study). *Diabetes Res Clin Pract in press.*
13. Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, **Miyoshi H\***. Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneeligliptin: Secondary Analyses of the CALMER study. *J Diabetes Invest.* 13498, 2021
14. Miyoshi A, Kameda H, Nagai S, Nakamura A, Miya A, Takase T, Atsumi T, **Miyoshi H\***. Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteoporosis. *J Diabetes Invest.* 13458, 2020
15. Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Nakamura A, Atsumi T, **Miyoshi H\***. Effects of switching from liraglutide or dulaglutide to subcutaneous semaglutide on glucose metabolism and treatment satisfaction in patients with type 2 diabetes: protocol for a multi-center, prospective, randomized, open-label, blinded endpoint parallel-group comparison study (the SWITCH-SEMA 1 Study). *Diabetes Ther.* 12(3), 955-964, 2021
16. Oba-Yamamoto C, Takeuchi J, Nakamura A, Takikawa R, Ozaki A, Nomoto H, Kameda H, Cho KY, Atsumi T, **Miyoshi H\***. Combination of alcohol and glucose consumption as a risk to induce reactive hypoglycemia. *J Diabetes Invest.* 12:651-657, 2021
17. Chiba K, Nomoto H, Nakamura A, Cho KY, Miya A, Kameda H, Kurihara Y, Aoki S, Atsumi T, **Miyoshi H\***. SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes. *J Diabetes Invest.* 12:176-183, 2021
18. Nakamura A, **Miyoshi H**, Ukawa S, Nakamura K, Terauchi Y, Tamakoshi A, Atsumi T. Inverse association between serum high-molecular-weight adiponectin level and proinsulin level in a general Japanese population: the DOSANCO Health Study. *J Diabetes Invest.* 12:63-66, 2021
19. Omori K, Nakamura A, **Miyoshi H**, Yamauchi Y, Kawata S, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Terauchi Y, Atsumi T. Glucokinase inactivation paradoxically ameliorates glucose intolerance by increasing beta-cell mass in db/db mice. *Diabetes.* 70:917-931, 2021
20. Kamoshima H, Nomoto H, Yamashita K, Takahashi Y, Tsuchida K, Kuwabara S, Miya A, Cho KY,

Kmeda H, Nakamura A, Atsumi T, Taneda S, Kurihara Y, Aoki S, Ono Y, Miyoshi H\*. Do the benefits of sodium-glucose cotransporter 2 inhibitors exceed the risks in patients with type 1 diabetes? *Endocrine J. in press*

21. Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H\*. Switching from insulin degludec plus dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide improves glycemic variability in patients with type 2 diabetes: a preliminary prospective observation study. *J Diabetes Res*, in press.
22. Miya A, Nakamura A, Handa T, Nomoto H, Kameda H, Cho KY, Nagai S, Ito Y, Miyoshi H, Atsumi T. Log-linear relationship between endogenous insulin secretion and glycemic variability in patients with type 2 diabetes on continuous glucose monitoring. *Sci Rep*. 11:9057, 2021
23. Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H\*. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin. *J Diabetes Investig*. 12:1395-1399, 2021.
24. Handa T, Nakamura A, Miya A, Nomoto H, Kameda H, Cho KY, Nagai S, Yoshioka N, Miyoshi H, Atsumi T. The association between hypoglycemia and glycemic variability in elderly patients with type 2 diabetes: prospective observational study. *Diabetol & Metabo Syndr*. 13:37, 2021
25. Yamauchi Y, Kameda H, Nakamura A, Cho KY, Nomoto H, Omori K, Tani M, Miyoshi H, Atsumi T. Severe infection including disseminated herpes zoster triggered by subclinical Cushing's disease: a case report. *BMC endocr disord*. 21:84, 2021
26. Tsuchida K, Nakamura A, Miyoshi H, Yang K, Yamauchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T. Glucokinase is required for high-starch diet-induced beta-cell mass expansion in mice. *J Diabetes Invest*. 13:532, 2021
27. Sekizaki T, Kameda H, Nakamura A, Cho KY, Nomoto H, Takahashi K, Wada N, Takeuchi J, Nagai S, Miyoshi H, Atsumi T. Does dipeptidyl peptidase-4 inhibitor exacerbate Graves' disease? *J Diabetes Invest*. 2021 in press
28. Baba N, Kameda H, Nakamura A, Cho KY, Nomoto H, Mitsuhashi T, Miyoshi H, Atsumi T. Silent pituitary adenoma and metabolic disorders: obesity, abnormal glucose tolerance, hypertension and dyslipidemia. *Endocrine J*. 68:195-200, 2021
29. Yamamoto C, Kameda H, Miyoshi H, Takase T, Fujita Y, Nomoto H, Cho KY, Nakamura A, Atsumi T. Acromegaly cases exhibiting increased growth hormone during dipeptidyl peptidase-4 inhibitor preadministered oral glucose loading compared to oral glucose loading. *Intern Med*. 2021 in press
30. Suzuki K, Suda G, Yamamoto Y, Furuya K, Nakamura A, Miyoshi H, Ogawa K, Ohnishi S, Sakamoto N; NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. *J Gastroenterol*. 2021;56(2):168-180.
31. Yuno A, Kenmotsu Y, Takahashi Y, Kameda H, Miyoshi H, Atsumi T, Sawamura Y, Akira Shimatsu.

Successful management of active Cushing's disease complicated with COVID-19 pneumonia. *Endocr J*. 68:477-484, 2021

32. Oe Y, Kameda H, Nomoto H, Sakamoto K, Soyama T, Cho KY, Nakamura A, Iwasaki K, Abo D, Kudo K, Miyoshi H, Atsumi T. Favorable effects of burosunab on tumor-induced osteomalacia caused by an undetectable tumor: a case report. *Medicine*. 2021 *in press*
33. Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T, and the J-BRAND Registry Group. Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry). *BMJ Open Diabetes Res Care*. 9:e001787, 2021
34. Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Nakamura A, Miyoshi H, Atsumi T, Iseki K. The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. *Drug Metab Pharmacokinet*. 37:100376, 2021
35. Endo T, Koike Y, Hisada Y, Tanaka M, Tsujimoto T, Ito Y, Miyoshi H, Iwasaki N, Takahata M. Association between fatty liver and early-onset ossification of the posterior longitudinal ligament of the spine. *Sci Rep*. *in press*

## 2020

36. Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H\*. Favorable effect of the SGLT2 inhibitor canagliflozin plus the DPP-4 inhibitor teneligliptin in combination on glycemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study). *Diabetes Obes Metab*. 22:458-462.2020
37. Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T, Miyoshi H\*, Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicenter, prospective, randomized, open-label, blinded endpoint parallel-group comparison study. *BMJ Open*. 10(2):e034883.2020
38. Cho KY, Nomoto H, Nakamura A, Omori K, Takase T, Miya A, Nomoto H, Kameda H, Taneda S, Kurihara Y, Aoki S, Atsumi T, Miyoshi H\*. Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone. *J Diabetes Invest*. 13457, 2020
39. Nakamura A, Miyoshi H\*, Kameda H, Yamashita K, Kurihara Y. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. *Diabetol Metab Syndr*. 12:4, 2020
40. Cho KY, Nakamura A, Yamamoto C, Tsuchida K, Yanagiya S, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H\*. Switching to once-daily insulin degludec/insulin aspart from basal insulin improves postprandial glycemia in patients with type2 diabetes: randomized controlled trial. *Diabetes &*

*Metabolism Journal.* 44:532-541, 2020

41. Sato M, Miyoshi H, Nakamura A, Sumi N, Kamoshima H, Ono Y. Cross-Cultural Adaptation of the Chronic Illness Resources Survey in Japanese Patients with Diabetes. *J Nurs Sci.* 17:e12279, 2020
42. Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Correlation between serum proinsulin levels and fatty liver: the DOSANCO Health Study. *J Diabetes Invest.* 11:964-970, 2020
43. Miya A, Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment. *J Diabetes Invest.* 2020 *in press*
44. Takase T, Nakamura A, Handa T, Nomoto H, Kameda H, Cho KY, Nagai S, Miyoshi H, Atsumi T. Effects of *Palmaria palmata* on lipid metabolism and glycemic control in participants with hypercholesterolemia in a randomized double-blind placebo-controlled trial. *Phytotherapy Research* 34:2303-2312, 2020.
45. Higuchi I, Kimura Y, Kobayashi M, Miyoshi H, Nakamura A, Atsumi T, Iseki K. Relationships between plasma lactate, plasma alanine, genetic variations in lactate transporters and type 2 diabetes in the Japanese population. *Drug Metab Pharmacokinet.* 35:131-138, 2020

## 2019

46. Cho KY, Nakamura A, Omori K, Takase T, Miya A, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H\*. Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial. *Diabetes Obes Metab.* 21:710-714, 2019
47. Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y. The protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease, and type 2 diabetes. *J Diabetes Invest.* 10:1510-1517, 2019
48. Takahashi K, Cho KY, Nakamura A, Miya A, Miyoshi A, Yamamoto C, Nomoto H, Niwa H, Takahashi K, Manda N, Kurihara Y, Aoki S, Ito Y, Atsumi T, Miyoshi H\*. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicentre observational study in Japanese patients with type 2 diabetes. *J Diabetes Invest.* 10:429-438, 2019
49. Omori K, Nomoto H, Nakamura A, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H\*. Reduction of glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: a randomized controlled trial of repaglinide vs. sulfonylurea. *J Diabetes Invest.* 10:367-374, 2019
50. Omori K, Nakamura A, Miyoshi H, Takase T, Cho KY, Ono K, Manda N, Kurihara Y, Aoki S, Atsumi T. Effects of dapagliflozin and/or insulin glargine on beta cell mass and hepatic steatosis in db/db mice. *Metabolism.* 98:27-36, 2019
51. Shibayama Y, Kameda H, Ohta S, Cho KY, Nakamura A, Miyoshi H, Atsumi T. A case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab. *J Diabetes*

*Invest.* 10:1385-1387, 2019

52. Nomoto H, Kameda H, Nakamura A, Tsuchida K, Yamamoto C, Nagai S, Atsumi T, Miyoshi H\*. Breakdown of autonomously functioning thyroid nodule accompanied by acromegaly after octreotide treatment. *Frontiers in Endocrinology*. 10:131. eCollection 2019
53. Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, Cho KY, Kurihara Y, Manda N, Aoki S, Atsumi T, Miyoshi H\*. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial. *J Diabetes Invest.* 10:699-705, 2019
54. Yamauchi Y, Nakamura Y, Takahashi K, Takase T, Yamamoto C, Atsumi T. Miyoshi H\*. Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin. *Endocr J.* 66:995-1000, 2019
55. Sekizaki T, Kameda H, Nakamura A, Miyoshi H, Atsumi T. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation. *Endocr J.* 66:937-941, 2019.
56. Miya A, Nakamura A, Miyoshi H, Atsumi T. Gitelman's Syndrome with hyperphosphatemia, effectively responding to single oral magnesium oxide administration. *Medicine.* 98(28):e16408. 2019

## 2018

57. Yamamoto K, Miyoshi H\*, Cho KY, Nakamura A, Greenberg AS, Atsumi T. Overexpression of Perilipin1 protects against atheroma progression in apolipoprotein E knockout mice. *Atherosclerosis.* 269: 192-196, 2018
58. Kitao N, Miyoshi H\*, Furumoto T, et al. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). *Cardiovasc Diabetol.* 16: 125, 2018
59. Takase T, Nakamura A, Yamamoto C, Atsumi T, Miyoshi H\*. Improvement in the proinsulin/C-peptide ratio during treatment with ipragliflozin in Japanese patients with type 2 diabetes mellitus. *Expert Opinion on Pharmacotherapy.* 19: 631-632, 2018
60. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: a direct or inverse association? *J Diabetes Invest.* 9: 1106-1109, 2018
61. Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. Effect Impact of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages. *Sci Rep.* 8(1):6864, 2018
62. Niwa H, Takahashi K, Dannoura M, Oomori K, Miyoshi A, Inada T, Miyoshi H. The association of cardio-ankle vascular index and ankle brachial index with macroangiopathy in patients with type 2 diabetes mellitus. *J Atheroscler Thromb.* 26:616-623, 2018
63. Nakamura A, Miyoshi H, Ukawa S, Nakamura K, Nakagawa T, Terauchi Y, Tamakoshi A, Atsumi T. Serum adiponectin and insulin secretion: A direct or inverse association? DOSANCO Health Study.

*J Diabetes Invest.* 9:1106-1109, 2018

64. Kitao N, Nakamura A, Miyoshi H, Nomoto H, Takahashi K, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T. The role of glucokinase and insulin receptor substrate-2 in the proliferation of pancreatic beta cells induced by short-term high-fat diet feeding in mice. *Metabolism.* 85: 48-58, 2018
65. Miya A, Nakamura A, Miyoshi H, Takano Y, Atsumi T. Impact of glucose loading on variations in CD4+ and CD8+ T cells in Japanese participants with or without type 2 diabetes. *Frontiers in Endocrinology* (Lausanne). 9:81, 2018
66. Yamamoto K, Miyoshi H\*, Cho KY, Nakamura A, Greenberg AS, Atsumi T. The data of change in macrophage gene expression which induced by perilipin 1 overexpression. *Data in Brief.* 19:179-182, 2018
67. Nomoto H, Miyoshi H\*, Sekizaki T, Atsumi T. Comment on 'Elevation of Serum Carcinoembryonic Antigen Concentration Caused by Everolimus-Induced Lung Injury: A Case Report'. *Ann Thorac Cardiovasc Surg.* 24: 165-166, 2018
68. Nomoto H, Miyoshi H\*, Nakamura A, et al. Potential Importance of a Histopathological Analysis in Thyroidal Diseases with High Serum IgG4 Levels. *Intern Med.* 57:453, 2018
69. Oita Y, Miyoshi H\*, Ono K, et al. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes - Randomized controlled study-. *Endocrine J.* 65: 141-150, 2018
70. Ynagiya S, Cho KY, Nakamura A, Nomoto H, Kawamoto Y, Miyoshi H, Atsumi T. The effect of everolimus on refractory hypoglycemia in a patient with inoperable metastatic insulinoma evaluated by continuous glucose monitoring. *Intern Med.* 57:2527-2531, 2018
71. Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, Miyoshi H, Sakamoto N. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. *PLoS One.* 13(12):e0209615, 2018.
72. Ujiie H, Muramatsu K, Mushiroda T, Ozeki T, Miyoshi H, Iwata H, Nakamura A, Nomoto H, Cho KY, Sato N, Nishimura M, Ito T, Izumi K, Nishie W, Shimizu H. HLA-DQB1\*03:01 as a biomarker for genetic susceptibility to bullous pemphigoid induced by DPP-4 inhibitors. *J Invest Dermatol.* 138: 1201-1204, 2018

## 2017

73. Kondo A, Nakamura A, Takeuchi J, Miyoshi H, Atsumi T. Insulin-induced distant-site lipotrophy. *Diabetes Care.* 40(6):e67-e68, 2017.
74. Nomoto H, Miyoshi H\*. Review: The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes. *Br J Res.* 4(3):21: 1-5, 2017
75. Nomoto H, Miyoshi H\*, Sugawara H, Ono K, Yanagiya S, Oita M, Nakamura A, Atsumi T. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. *Diabetol Metab Syndr.* 17:9:54, 2017

76. Miya A, Nakamura A, Miyoshi H<sup>\*</sup>, Cho KY, et al. Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: a randomized controlled trial. *J Diabetes Invest.* 9:119-126, 2017
77. Nomoto H, Miyoshi H<sup>\*</sup>, Nakamura A, et al. A case of osteomalacia, due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report. *Medicine.* 96(39):e8147, 2017
78. Ohtaka K, Fujisawa Y, Takada F, Hasegawa Y, Miyoshi T, Miyoshi H, Fukami M, Ogata T. FGFR1 Mutations in four patients with hypogonadotropic hypogonadism and split-hand/foot malformation: Implications for the FGFR1 promoter region. *Human Mutation.* 38(5):503-506, 2017.
79. Nakamura A, Iwami D, Miyoshi H<sup>\*</sup>, Morita K, Taguri M, Terauchi Y, Shinohara N, Atsumi T. Impact of renal transplantation on glucose tolerance in Japanese recipients with impaired glucose tolerance. *Diabetic Med.* 34(4):569-576, 2017.
80. Nomoto H, Miyoshi H<sup>\*</sup>, Nakamura A, Atsumi T, Manda N, Kurihara Y, Aoki S. Do DPP-4 inhibitors improve endothelial cell function? *Curren Tren Cardiol.* 1: 10-13, 2017
81. Nomoto H, Kimachi K, Miyoshi H<sup>\*</sup>, Kameda H, Cho KY, Nakamura A, Nagai S, Kondo T, Atsumi T. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. *Endocr J.* 29; 64(4):417-424, 2017.
82. Nomoto H, Miyoshi H<sup>\*</sup>, Nakamura A, Atsumi T, Manda N, Kurihara Y, Aoki S. Impact of incretin related-agents on endothelial cell function. *Clin Trials Degener Dis.* 2:7-11,2017.
83. Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, et al. Isolated adrenocorticotrophic hormone deficiency associated with nivolumab therapy. *J Dermatol.* 44(4):e70, 2017.
84. Takase T, Nakamura A, Miyoshi H<sup>\*</sup>, et al. Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects. *Endocr J.* 31; 64(3):363-367, 2017.
85. Iwami D, Nakamura A, Hotta K, Sasaki H, Hirose T, Higuchi H, Takada Y, Miyoshi H, Shinohara N. Glucose Tolerance After Kidney Transplant Is Affected by Systemic Insulin Sensitivity Rather Than Usage of Tacrolimus. *Am J Transplant.* 17(3): 759-759, 2017.
86. Cho KY, Miyoshi H, Nakamura A, et al. Hyponatremia can be a powerful predictor for the development of nivolumab associated isolated ACTH deficiency. *Endocr J.* 27; 64(2):235-236, 2017.
87. Narahira A, Yanagi T, Cho KY, Nakamura A, Miyoshi H, Hata H, Imafuku K, Kitamura S, Shimizu H. Isolated adrenocorticotrophic hormone deficiency associated with nivolumab therapy. *J Dermatol.* 2017;44(4):e70.
88. Takahashi K, Nakamura A, Miyoshi H<sup>\*</sup>, et al. Factors associated with an ineffective stimulus in the insulin tolerance test in Japanese patients with suspected or proven hypopituitarism. *Endocr J.* 29;64(4):387-392, 2017.



89. Nomoto H, Miyoshi H\*, Furumoto T, Oba K, Tsutsui H, Inoue A, Atsumi T, Manda N, Kurihara Y, Aoki S. SAIS Study Group. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1). *PLoS One*. 6: 11(10):e0164255, 2016.
90. Yamamoto C, Miyoshi H\*, Ono K, et al. Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy. *Endocrine J*. 63(6):589-96, 2016.
91. Miyoshi A, Yamada M, Shida H, Miyoshi H, et al. Circulating NET levels in well-controlled type 2 diabetes and pathway involved in high-dose glucose-induced NET formation. *Pathobiology*. 83: 243-251, 2016.
92. Koyanagawa N, Miyoshi H\*, Ono K, Nakamura A, et al. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus. *Endocr J*. 31;63(8):747-53, 2016
93. Yamamoto C, Miyoshi H\*, Atsumi T. Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus. *Endocr J*. 63(1):53-60, 2016.
94. Nakamura A, Mitsuhashi T, Takano Y, Kameda H, Nomoto H, Nagai S, Miyoshi H\*, Shimizu C, Terauchi Y, Atsumi T. Usefulness of the octreotide test in Japanese patients for predicting the presence/absence of somatostatin receptor 2 expression in insulinomas. *Endocr J*. 63(2):135-42, 2016.
95. Nakamura A, Terauchi Y, Miyoshi H, Koike T. Glucokinase: Role in whole-body glucose homeostasis. *Journal of Diabetes Research*. 2016
96. Komatsu Y, Nakamura A, Takihata M, Inoue Y, Yahagi S, Tajima K, Tsuchiya H, Takano T, Yamakawa T, Yoshida M, Miyoshi H, Terauchi Y. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. *Endocr J*. 63: 311-314, 2016
97. Nomoto H, Miyoshi H\*. A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial. Sapporo Athero-Incretin Study 2 (SAIS2). *World Biomedical Frontiers* ISSN: 2328-0166. 2016.
98. Nomoto H, Miyoshi H\*, Furumoto T, Oba K, Tsutsui H, Atsumi T, Aoki S, et al. A Comparison of the effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial. Sapporo Athero-Incretin Study 2 (SAIS2). *PLoS One*. 10 (8): e0135854, 2015
99. Nomoto H, Kondo T, Miyoshi H, Nakamura A, Hida Y, Yamashita KI, Sharma AJ, Atsumi T. Inhibition of small Maf function in pancreatic beta cells improves glucose tolerance through the enhancement of insulin gene transcription and insulin secretion. *Endocrinology*. 156(10):3570-80, 2015.
100. Kameda H, Miyoshi H, Shimizu C, Atsumi T. Expression and regulation of neuromedin B in pituitary corticotrophs of male melanocortin 2 receptor-deficient mice. *Endocrinology*. 155(7):2492-9, 2014
101. Miya A, Nakamura A, Miyoshi H, Kameda H, Nomoto H, Nagai S, Omori Y, Hatanaka CK, Kobayashi H, Shimizu C, Atsumi T. Glucose tolerance is improved following surgery for silent

- somatotroph adenoma. *Int J Diabetes Clin Res.* 2: 047, 2015
102. Matsui Y, Tomaru U, Miyoshi A, Ito T, Fukaya S, Miyoshi H, Atsumi T, Ishizu A. Overexpression of TNF- $\alpha$  converting enzyme promotes adipose tissue inflammation and fibrosis induced by high fat diet. *Exp Mol Pathol.* 97(3):354-8, 2014.
103. Yong KC, Nakagaki O, Miyoshi H\*, Akikawa K, Atsumi T. Evaluation of thrice-daily injections of insulin Lispro Mix 50/50 versus basal-bolus therapy in perioperative patients with type 2 diabetes. *Diabetol Int.* 2014.
104. Kimachi K, Miyoshi H\*. Infectious disease associated with diabetes mellitus--mechanisms, classification, diagnosis and therapy. *Nihon Rinsho. Japanese journal of clinical medicine*, 2012
105. Nakamura A, Yoneda M, Sumida Y, Miyoshi H, Nakajima A, Atsumi T, Terauchi Y. A caution in the use of the NAFIC scoring system as a diagnostic screening tool for nonalcoholic steatohepatitis. *J Gastroint Dig Syst.* 4: 221, 2014
106. Nakagaki O, Miyoshi H\*, Sawada T, Atsumi T, Kondo T, Atsumi T. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor. *Exp Clin Endocrinol Diabetes.* 21: 1-6, 2013.
107. Miyoshi A, Nagai S, Takeda M, Kondo T, Nomoto H, Kameda H, Hirai A, Cho K, Kimachi K, Shimizu C, Atsumi T, Miyoshi H\*. Ovarian morphology and prevalence of polycystic ovary syndrome in Japanese women with type 1 diabetes mellitus. *J Diabetes Invest.* 4(3):326-329, 2013.
108. Yong KC, Miyoshi H\*, Kuroda S, Yasuda H, Kamiyama K, Nakagawara J, Takigami M, Kondo T, Atsumi T. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. *J Stroke Cerebrovasc Dis.* 22(7):910-8, 2013.
109. Tajima K, Nagai S, Miyoshi H, et al : A comparison of pregnancy outcomes in Japanese women with type 2 and type 1 diabetes mellitus at tertiary centers. *Diabetol Int.* 2:86-93, 2011
110. Miyoshi H\*. Perilipin. *Nihon rinsho. Japanese journal of clinical medicine*, 2011
111. Nanjo K, Nagai S, Shimizu C, Tajima T, Kondo T, Miyoshi H, Yoshioka N, Koike T. Identification and functional analysis of novel calcium-sensing receptor gene mutation in familial hypocalciuric hypercalcemia. *Endocr J.* 29;57(9):787-92, 2010
112. Nakamura A, Shimizu C, Nagai S, Kondo T, Miyoshi H, Tajima T, Terauchi Y, Yoshioka N, Koike T. Problems in diagnosing atypical Gitelman's syndrome presenting with normomagneseamia. *Clin Endocrinol.* 72(2):272-6. 2010
113. Sawada T, Miyoshi H\*, Shimada K, Suzuki A, Okamatsu-Ogura Y, Koike T. Perilipin Overexpression in White Adipose Tissue Induces a Brown Fat-like Phenotype. *PLoS One.* 5(11):e14006, 2010
114. Miyoshi H, Souza SC, Endo M, Sawada T, Perfield JW 2nd, Shimizu C, Stancheva Z, Nagai S, Strissel KJ, Yoshioka N, Obin MS, Koike T, Greenberg AS. Perilipin overexpression in mice protects against diet-induced obesity. *J Lipid Res.* 51(5): 975-82, 2010
115. Greenberg AS, Coleman RA, Kraemer FB, McManaman JL, Obin MS, Puri V, Yan QW, Miyoshi H, Mashek DG. The role of lipid droplets in metabolic disease in rodents and humans.

~2009 (留学帰国前)

116. Shen WJ, Patel S, **Miyoshi H**, Greenberg AS, Kraemer FB. Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. *J Lipid Res.* 50(11): 2306-13, 2009
117. **Miyoshi H**, Perfield JM, Obin MS, Greenberg AS. Adipose triglyceride lipase regulates basal lipolysis and lipid droplet size in adipocytes. *J Cell Biochem.* 105: 1430-1436, 2008
118. Gauthier MS, **Miyoshi H**, Souza SC, Cacicedo JM, Saha AK, Greenberg AS, Ruderman NB. AMP-activated protein kinase (AMPK) is activated as a consequence of lipolysis in the adipocyte: potential mechanism and physiological relevance. *J Biol Chem.* 283(24):16514-24, 2008
119. **Miyoshi H**, Perfield JM, Souza SC, Shen WJ, Zhang HH, Stancheva ZS, Kraemer FB, Obin MS, Greenberg AS. Control of ATGL action by serine 517 of perilipin A globally regulates PKA-stimulated lipolysis in adipocytes. *J Biol Chem.* 282(2):996-1002, 2007
120. Strissel KJ, Stancheva Z, **Miyoshi H**, DeFuria J, Jick Z, Greenberg AS, Obin MS. Adipocyte death, adipose tissue remodeling and obesity complications. *Diabetes.* 56(12):2910-8, 2007
121. Souza SC, Christoffolete MA, Ribeiro MO, **Miyoshi H**, Strissel KJ, Stancheva ZS, D'Eon TM, Perfield JW, Imachi H, Obin MS, Bianco AC, Greenberg AS. Perilipin regulates the thermogenic actions of norepinephrine in brown adipose tissue. *J Lipid Res.* 48(6):1273-9, 2007
122. Gross DN, **Miyoshi H**, Hosaka T, Zhang HH, Pino EC, Souza S, Obin M, Greenberg AS, Pilch PF. Dynamics of lipid droplet associated proteins during hormonally stimulated lipolysis in engineered adipocytes: Stabilization and lipid droplet binding of ADRP/adipophilin. *Mol Endocrinol.* 20(2):459-66, 2006
123. **Miyoshi H**, Souza SC, Zhang HH, Strissel KJ, Christoffolete MA, Kovsan J, Rudich A, Kraemer FB, Bianco AC, Obin MS, Greenberg AS. Perilipin promotes hormone-sensitive lipase-mediated adipocyte lipolysis via phosphorylation-dependent and -independent mechanisms. *J Biol Chem.* 281(23):15837-44, 2006
124. Suzuki F, Shimizu C, Umetsu M, Nagai S, Takeuchi J, Endo M, **Miyoshi H**, Yoshioka N, Kubo M and Koike T. Adult-onset idiopathic hypogonadotropic hypogonadism due to isolated pituitary gonadotropin deficiency. *Internal Med*, 43, 571-4, 2004
125. Nagai S, Shimizu C, Umetsu M, Taniguchi S, Endo M, **Miyoshi H**, Yoshioka N, Kubo M, and Koike T. Identification of a functional peroxisome proliferator-activated receptor responsive element within the murine perilipin gene. *Endocrinology*, 145, 2346-56, 2004
126. **Miyoshi H**, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Miwa I, Makita Z, and Koike T. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. *Horm Metab Res*, 34, 371-7, 2002
127. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, **Miyoshi H**, and Koike T. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end-product inhibitor, OPB-9195, *Diabetologia*, 42, 579-588, 1999